Skip to main content
. Author manuscript; available in PMC: 2022 Oct 13.
Published in final edited form as: Oncogene. 2022 Apr 13;41(20):2824–2832. doi: 10.1038/s41388-022-02307-9

Figure 1. KIF20A expression increases with prostate cancer progression and is prognostic for poor outcome.

Figure 1.

(A) KIF20A expression in normal or benign prostate, PC, CRPC and metastatic sites was obtained from RNA-seq datasets through cBioPortal and the Xena Browser. Significance was tested using the p-adjusted method, and expression values are plotted for visualization. TCGA-PRAD (The Cancer Genome Atlas-Prostate Adenocarcinoma); MSKCC (Memorial Sloan Kettering Cancer Center) (B) Microarray datasets (Varambally = GSE3325; Aryee = GSE38241; Ross-Adams = GSE70770) of prostate cancer patient samples. Significance was calculated using the p-adjusted method in GEO2R, and expression values are plotted for visualization. (C) KIF20A expression from microarray data (GSE169038) correlated with Gleason and Decipher score. (D) KIF20A expression correlated with Progression Free Survival was analyzed in the Xena Browser. 5.606 is the median expression for all PC samples. NS = Not significant; * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001. Error bars = SEM